The BARDA contract provides non-dilutive capital that de-risks SCY-247 development and extends the company's cash runway. Monitor for BARDA exercising additional options and Phase 2 trial initiation for SCY-247, which would further validate the program.
Price Chart
Executive Summary
SCYNEXIS announced a BARDA contract worth up to ~$214M (if all options exercised) to fund development of SCY-247, its second-generation antifungal candidate, through NDA submission for two indications. The initial base period provides ~$18.5M to advance SCY-247 into Phase 2 for invasive candidiasis. The company's existing guidance for SCY-770 and cash runway into 2029 remains unchanged.
Key Financial Metrics
Key Facts
- BARDA contract provides up to ~$214M in potential funding if all options are exercised
- Initial base period provides ~$18.5M to advance SCY-247 into Phase 2 for invasive candidiasis
- Contract may be extended for up to 10 years
- SCY-247 has Orphan, QIDP and Fast Track designations from FDA
- Company's cash runway into 2029 and SCY-770 development plans remain unchanged
- Non-dilutive funding strengthens pipeline without impacting existing operating plan
Financial Impact
Up to ~$214M in potential non-dilutive funding over 10 years; initial ~$18.5M base period funding
Risk Factors
- BARDA may not exercise all options, limiting total funding to the initial ~$18.5M
- SCY-247 is still pre-Phase 2; clinical trial risks remain
- Company's primary focus remains SCY-770 for ADPKD, which is still in development
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3369788 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 22, 2026 4d ago | Press Release | $3.81 | awaiting T+5 | — | $3.81 (−0.00%) |
Oct 6, 2026 21d ago | Press Release | $4.84 $3.99 | ▼ −17.56% | ▼ −17.42% | $3.81 (−21.28%) |
Sep 28, 2026 29d ago | Press Release | $4.62 $5.03 | ▲ +8.87% | ▲ +7.67% | $3.81 (−17.53%) |
Sep 22, 2026 4w ago | 8-K | $4.86 $4.66 | ▼ −4.12% | ▼ −2.93% | $3.81 (−21.60%) |
Sep 10, 2026 6w ago | 8-K | $4.70 $4.45 | ▼ −5.32% | ▼ −4.82% | $3.81 (−18.94%) |
Jun 26, 2026 17w ago | 8-K | $3.87 $4.73 | ▲ +22.22% | ▲ +20.83% | $3.81 (−1.55%) |
May 22, 2026 22w ago | 8-K | $5.45 $5.33 | ▼ −2.17% | ▼ −3.25% | $3.81 (−30.07%) |
May 11, 2026 24w ago | Press Release | $6.24 $5.26 | ▲ +15.77% | ▲ +15.17% | $3.81 (+38.94%) |
Apr 20, 2026 27w ago | 8-K | $8.48 $7.89 | ▼ −6.98% | ▼ −8.06% | $3.81 (−55.07%) |
Mar 31, 2026 30w ago | Press Release | $7.34 $7.97 | ▲ +8.62% | ▲ +4.67% | $3.81 (−48.06%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers